Our solutions
-
Passionate about
your product - IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.
-
Helping you to help
patients - Our goal is to attain the best possible results for patients, by understanding the goals of our clients, cooperating with authorities, and utilising available regulatory incentives to accelerate assessment, while delivering quality data for regulatory approval.
-
Working as part of
your team - We work as part of your team and are fully with you on your regulatory journey, helping to navigate the complex and ever-evolving global regulatory and market access environments, pre-empting and managing the common misunderstandings that can cause you unexpected costs and delays.
-
Quality and
Pragmatism - By harmonising pharmaceutical Quality By Design principles with your business goals, we deliver dynamic regulatory strategies to help you recognise your product’s full potential. Avenues of communication will always be clear, helpful, easy and proportionate.
What is the right EMA initiative for your innovative medicine development programme?
Developers looking to bring their products to the European Union are often unaware of the different pathways open to them to get regulatory support. The European Medicines Agency (EMA) offers several initiatives to support innovators. However, there is some nuance to understanding which of these might be right for a developer, and at what stage […]
Early opportunities: What you should know about EMA’s rare disease incentives
Encouraging innovation is an overarching objective of the European Medicines Agency (EMA), with significant emphasis on supporting the development of medicines for rare diseases. With 36 million people in the European Union living with a rare disease, the EU offers various incentives to encourage the development of designated orphan medicines. What are these programmes and […]
MHRA taps into expertise to drive innovation for rare diseases in UK
The UK has long been renowned for its commitment to innovation and progressive regulatory approaches to pharmaceutical development. There were concerns that separating from the European Union would hinder the UK. However, one welcome, if unexpected, consequence of Brexit has been the emergence of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as an […]
-
London Office
-
- Metal Box Factory
- 30 Great Guildford Street
- Borough
- SE1 0HS
- United Kingdom
-
Munich Office
-
- Albrechtstrasse 43 RG
- 80636 München
- Germany
-
Dublin Office
-
- 13 Classon House
- Dundrum Business Park
- Dundrum, Dublin D14 W9Y3
- Republic of Ireland